Objective: Along with the increasing prevalence of obesity and related diseases, particularly atherosclerotic diseases, metabolic syndrome (MetS) is now a common and major public health issue in many countries around the world. Adiponectin, a protein secreted by the adipose tissue, has become recognized as a key player in the development of MetS. These days, not only MetS but also borderline metabolic/physiological abnormalities, such as impaired fasting glucose, high normal blood pressure and high normal plasma cholesterol, have been reported to be risk factors for atherosclerotic disease. Therefore, we undertook this study to determine the relationship between adiponectin and borderline metabolic/physiological abnormalities, as well as MetS. Design: A cross-sectional study performed from April 2007 to November 2009. Subjects: In 16 892 Japanese adults (10 008 men and 6884 women), we examined the relationship between the serum adiponectin concentration and borderline metabolic/physiological abnormalities or MetS by a questionnaire survey about medical treatment, body size measurement and measurement of laboratory parameters including the serum adiponectin concentration.
Introduction
In recent years, the increased prevalence of obesity has led to an increase of related diseases, especially atherosclerotic diseases such as cardiovascular and cerebrovascular disease, which are now responsible for high levels of morbidity and mortality. 1 Many of these patients have metabolic syndrome (MetS), which arises from the accumulation of visceral fat. 2 Thus, MetS has become a major public health issue in many countries around the world.
To identify the molecular mechanisms underlying diseases related to visceral obesity, the biological characteristics of the adipose tissue were investigated by analysis of the gene expression profile in fat, and revealed a gene named adiponectin. 3 Adiponectin is found at a relatively high concentration in human plasma, accounting for approximately 0.01% of total plasma protein, 4 and its level is inversely correlated with visceral adiposity. 5 Many studies have been performed on adiponectin and various components of the MetS. As a result, adiponectin has been reported to exhibit insulin-sensitizing, antiatherogenic and antiinflammatory effects. 6, 7 Conversely, low adiponectin levels are related to insulin resistance, an increased risk of type 2 diabetes, 8 hypertension, 9 dyslipidemia 10 and low plasma levels of high-density lipoprotein cholesterol. 10 Because of these documented associations, adiponectin is considered to have a key role in the development of MetS and its consequence, cardiovascular and cerebrovascular disease, 5, 11 and the regulation of adiponectin might be considered as an efficient therapeutic procedure. 2, 12 Several borderline metabolic and physiological abnormalities, such as impaired fasting glucose, high normal blood pressure (BP) and a high normal plasma level of low-density lipoprotein cholesterol, have also been reported to increase the risk of atherosclerotic disease. [13] [14] [15] [16] [17] However, there have been no studies of adiponectin levels in such subclinical populations. Therefore, we undertook this study to determine the relationship between adiponectin and borderline metabolic/physiological abnormalities, as well as MetS.
Subjects and methods
The subjects of this study were 16 892 adults (10 008 men and 6884 women) who had complete medical checkup at the Physical Check up Center in Sumitomo Hospital from April 2007 to November 2009. In Japan, people often had their medical checkup by their own will at a physical checkup center attached to some hospitals, in order to evaluate their health condition. The subjects of this study were those who were not patients visited to our hospital, and all of them had no apparent disease that required hospital admission. A questionnaire about medical treatment was completed, followed by the measurement of body size and blood tests (including the serum adiponectin concentration). BP was measured while they are sitting. All people who received medication of diabetes mellitus, hypertension and dyslipidemia were excluded. All participants signed informed consent to provide medical information and blood samples before undergoing the medical check up, and they had the right to refuse use of their data. , triglyceridesX150 and high-density lipoprotein cholesterolo40) was also done according to the criteria of these three societies.
The serum adiponectin level was used to divide the subjects into five groups, which were less than 4 mg ml À1 (hypoadiponectinemia), 22 more than 4 mg ml À1 and less than 7 mg ml
À1
, more than 7 mg ml À1 and less than 10 mg ml À1 , more than 10 mg ml À1 and less than 13 mg ml À1 and more than 13 mg ml
. Then the relationship between the adiponectin level and the number of MetS components, the presence/absence of borderline metabolic abnormalities and the waist circumference was examined. When investigating the number of borderline metabolic abnormalities, patients with clinically overt conditions such as diabetes, hypertension or dyslipidemia (5937 men and 2215 women) were excluded.
The serum adiponectin level was measured by a latex particle-enhanced turbidimeric immunoassay (Human adiponectin latex kit, Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan) as reported previously. 23 HbA lc (%) was converted to a 
Results

Clinical and biological characteristics
The clinical and biological characteristics of the participants are shown in Table 1 . On average, subjects without MetS were younger, had a smaller body mass index and waist circumference than those with MetS both in men and women. They also had a lower BP, fasting plasma glucose, hemoglobin Alc, homeostasis model assessment-insulin resistance and uric acid than the subjects with MetS, as well as a better lipid profile both in men and women. The mean serum adiponectin concentration was higher in people without MetS than those with MetS, being 8.3 vs 6.2 mg ml À1 in men and 13.3 vs 9.3 mg ml À1 in women, respectively (Po0.001).
One-way analysis of variance Adiponectin showed a significant negative correlation with the number of MetS components (Figure 1 ), the number of borderline metabolic abnormalities ( Figure 2 ) and the waist circumference ( Figure 3 ).
Multivariable analysis
According to multivariate analysis, the serum adiponectin concentration was negatively correlated with the number of MetS components (Table 2) . Body mass index, age, HOMA-R, uric acid and smoking habit showed a significant positive correlation with the number of MetS components, and sex (female) and creatinine showed a significant negative correlation with them. Similarly, after excluding the patients Number of metabolic syndrome with overt diabetes mellitus, hypertension and dyslipidemia, the serum adiponectin concentration was negatively correlated with the number of borderline metabolic abnormalities (Table 3) . Body mass index, age, HOMA-R and uric acid also showed a significant positive correlation with the number of high normal states, and smoking habit, sex (female) and creatinine showed a significant negative correlation with them.
Discussion
MetS is now well known to be a risk factor for the cardiovascular and cerebrovascular disease, and many studies have demonstrated an association between serum adiponectin levels and MetS. In recent years, borderline metabolic/physiological abnormalities, such as impaired fasting glucose, high normal BP and high normal plasma LDL cholesterol, have also been reported to be the risk factors for atherosclerotic disease. However, there has been no investigation of the relationship between the serum adiponectin level and such high normal states. Accordingly, this is the first large-scale investigation of the relationship between adiponectin and borderline metabolic/physiological abnormalities. The present study revealed several important findings. First, it confirmed a significant negative correlation between adiponectin and the number of MetS components, as previously reported. 24 Second, this study also showed a significant negative correlation between adiponectin and the number of borderline metabolic/physioligical abnormalities in a population from which overt diabetes, hypertension and dyslipidemia had been excluded. Although the association was not significant in women from the lowest adiponectin group (Figure 2) , this was probably due to the small number of women in the hypoadiponectinemia group (n ¼ 53). Third, the adiponectin level decreased significantly as the waist circumference increased. Though waist circumference is not the optimal measure of visceral fat, this result shows the association between serum adiponectin level and the amount of visceral fat, as it has been reported. 2 The decrease of adiopnectin is mainly caused by the accumulation of visceral fat, as well as genetic characteristics, and the present study showed that adiponectin starts to decline and its lack has adverse effects even in people with borderline metabolic/physiological abnormalities. It has been already reported that the adiponectin level is decreased in patients with excess visceral fat who have overt diabetes mellitus, hypertension, dyslipidemia or MetS. [8] [9] [10] [11] In addition, the present study suggests the possibility that the decrease of adiponectin may begin at an early stage when Abbreviations: BMI, body mass index; CI, confidence interval; Cr, serum creatinine; HOMA-IR, homeostasis model assessment-insulin resistance. B, partial regression coefficient; b, standard partial regression coefficient; P, significance probability. Objective variable, the number of metabolic syndrome components stepwise multiple regression analysis. Adiponectin and borderline abnormalities MY Baden et al
